In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model

被引:93
作者
Mandl, CW [1 ]
Aberle, JH [1 ]
Aberle, SW [1 ]
Holzmann, H [1 ]
Allison, SL [1 ]
Heinz, FX [1 ]
机构
[1] Univ Vienna, Inst Virol, A-1095 Vienna, Austria
关键词
D O I
10.1038/4031
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Live virus vaccines have in many cases proven to be an extremely effective tool for the prevention of viral diseases(1,2). However, the production of conventional live vaccines in eu; karyotic cell cultures has many disadvantages, including the potential for contamination with adventitious agents(3) and genetic alterations during propagation, making it necessary to do extensive testing before distribution(4,5). Based on results obtained with a flavivirus(6) (tick-borne encephalitis virus) in an experimental animal system, we propose a novel live attenuated virus vaccination strategy consisting of the application of in vitro-synthesized infectious RNA instead of the live virus itself. When administered using the GeneGun, less than 1 ng of RNA was required to initiate replication of virus that was attenuated by a specifically engineered deletion(7) and this induced a protective immunity in laboratory mice. Because this approach uses RNA, it does not have the potential drawbacks of DNA vaccines(8-10) and thus combines the advantages of conventional live virus vaccines(1,2) (for example, mimicking natural infection and inducing long-lasting immunity) with those of nucleic acid-based vaccines(2,8,11,12) (for example, ease of production without a requirement for eukaryotic cell culture, stability and purity).
引用
收藏
页码:1438 / 1440
页数:3
相关论文
共 20 条
[1]   Overview of vaccines [J].
Ada, G .
MOLECULAR BIOTECHNOLOGY, 1997, 8 (02) :123-134
[2]   Genetic immunization: a new era in vaccines and immune therapeutics [J].
Chattergoon, M ;
Boyer, J ;
Weiner, DB .
FASEB JOURNAL, 1997, 11 (10) :753-763
[3]  
Conry RM, 1996, SEMIN ONCOL, V23, P135
[4]   DNA vaccines [J].
Donnelly, JJ ;
Ulmer, JB ;
Shiver, JW ;
Liu, MA .
ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 :617-648
[5]   Genetic vaccines: Strategies for optimization [J].
Gregoriadis, G .
PHARMACEUTICAL RESEARCH, 1998, 15 (05) :661-670
[6]   A MODEL STUDY OF THE USE OF MONOCLONAL-ANTIBODIES IN CAPTURE ENZYME IMMUNOASSAYS FOR ANTIGEN QUANTIFICATION EXPLOITING THE EPITOPE MAP OF TICK-BORNE ENCEPHALITIS-VIRUS [J].
HEINZ, FX ;
TUMA, W ;
GUIRAKHOO, F ;
KUNZ, C .
JOURNAL OF BIOLOGICAL STANDARDIZATION, 1986, 14 (02) :133-141
[7]   Vaccine developments [J].
Liu, MA .
NATURE MEDICINE, 1998, 4 (05) :515-519
[8]   Infectious cDNA clones of tick-borne encephalitis virus European subtype prototypic strain Neudoerfl and high virulence strain Hypr [J].
Mandl, CW ;
Ecker, M ;
Holzmann, H ;
Kunz, C ;
Heinz, FX .
JOURNAL OF GENERAL VIROLOGY, 1997, 78 :1049-1057
[9]   Spontaneous and engineered deletions in the 3′ noncoding region of tick-borne encephalitis virus:: Construction of highly attenuated mutants of a flavivirus [J].
Mandl, CW ;
Holzmann, H ;
Meixner, T ;
Rauscher, S ;
Stadler, PF ;
Allison, SL ;
Heinz, FX .
JOURNAL OF VIROLOGY, 1998, 72 (03) :2132-2140
[10]   DNA vaccines - A modern gimmick or a boon to vaccinology? [J].
Manickan, E ;
Karem, KL ;
Rouse, BT .
CRITICAL REVIEWS IN IMMUNOLOGY, 1997, 17 (02) :139-154